### **Estimating the Impact of Alternative Programmatic Cotrimoxazole** 1 Strategies on Mortality Among Children Born to Mothers with HIV: 2 A Modelling Study 3

4	Shrey Mathur <sup>1</sup> , Melanie Smuk <sup>1</sup> , Ceri Evans <sup>1,2</sup> , Catherine J Wedderburn <sup>3,4</sup> , Diana M Gibb <sup>3</sup> , Martina
5	Penazzato <sup>5</sup> , Andrew J Prendergast <sup>1,2</sup>
6	
7	
8	
9	<sup>1</sup> Blizard Institute, Queen Mary University of London, London, United Kingdom
10	<sup>2</sup> Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
11	<sup>3</sup> Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom
12	<sup>4</sup> Department of Paediatrics and Child Health and Neuroscience Institute, University of Cape Town,
13	Cape Town, South Africa
14	<sup>5</sup> Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health
15	Organization, Geneva, Switzerland
16	
17	Corresponding author: Dr Shrey Mathur, Centre for Genomics and Child Health, Blizard Institute, 4
18	Newark Street, London E1 2AT, UK. <u>s.mathur@qmul.ac.uk</u>
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34 25	
35	
30 27	
38	Word count
20	Abstract: 333
40	Article: 3935

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 41 Abstract

4	2
-	~

## 43 BACKGROUND

44

World Health Organization guidelines recommend cotrimoxazole prophylaxis for children who are
HIV-exposed until infection is excluded and vertical transmission risk has ended. While cotrimoxazole
has benefits for children with HIV, there is no mortality benefit for children who are HIV-exposed but
uninfected, prompting a review of global guidelines. Here, we model the potential impact of

49 alternative cotrimoxazole strategies on mortality in children who are HIV-exposed.

50

## 51 METHODS AND FINDINGS

52

53 Using a deterministic compartmental model, we estimated mortality in children who are HIV-

54 exposed from 6 weeks to 2 years of age in four high-burden countries: Côte d'Ivoire, Mozambique,

55 Uganda, and Zimbabwe. Vertical transmission rates, testing rates, and antiretroviral therapy uptake

56 were derived from UNAIDS data, trial evidence, and meta-analyses. We explored six programmatic

57 strategies: maintaining current recommendations; shorter cotrimoxazole provision for three, six, nine

58 or twelve months; and starting cotrimoxazole only for children diagnosed with HIV.

59

60 Modelled alternatives to the current strategy increased mortality to varying degrees; countries with

61 high vertical transmission had the greatest mortality. Compared to current recommendations,

62 starting cotrimoxazole only after a positive HIV test had the greatest predicted increase in mortality:

63 Mozambique (961 excess annual deaths; excess mortality 339 per 100,000 HIV-exposed children; risk

64 ratio (RR) 1.06), Uganda (491; 221; RR 1.04), Zimbabwe (352; 260; RR 1.05), Côte d'Ivoire (125; 322;

65 RR 1.06). Similar effects were observed for three, six, nine, and twelve-month strategies. Increased

66 mortality persisted but was attenuated when modelling lower cotrimoxazole uptake, smaller

67 mortality benefits, higher testing coverage, and lower vertical transmission rates. The study is limited

68 by uncertain estimates of cotrimoxazole coverage in programmatic settings; an inability to model

69 increases in mortality arising from antimicrobial resistance due to limited surveillance data in sub-

70 Saharan Africa; and lack of a formal health economic analysis.

71

72 CONCLUSIONS

- 74 Changing current guidelines from universal cotrimoxazole provision for children who are HIV-
- rs exposed increased predicted mortality across the four modelled high-burden countries, depending
- on test-to-treat cascade coverage and vertical transmission rates. These findings can help inform
- policymaker deliberations on cotrimoxazole strategies, recognising that the risks and benefits differ
- 78 across settings.

## 80 Author Summary

81	
82	Why Was This Study Done?
83	Cotrimoxazole prophylaxis is recommended in World Health Organization (WHO) guidelines
84	for all children born to mothers with HIV until HIV infection has been excluded by an age-
85	appropriate HIV test to establish the final diagnosis after complete cessation of
86	breastfeeding.
87	• Though there is a proven mortality benefit for children who acquire HIV, recent trial evidence
88	has shown that cotrimoxazole does not reduce mortality for majority of children who are
89	HIV-exposed uninfected (HEU), which has led to countries considering changing their
90	guidelines.
91	In many resource-limited settings, however, it is difficult to reliably distinguish children with
92	HIV from children who are HEU, due to incomplete coverage of early infant diagnosis (EID) of
93	HIV.
94	• There is a need to model to what extent alternative cotrimoxazole strategies, which either do
95	not provide universal cotrimoxazole for all infants who are HIV-exposed, or provide it for a
96	shorter duration, would be predicted to increase mortality in different settings among
97	infants who acquire HIV but are undiagnosed.
98	
99	What Did the Researchers Do and Find?
100	This study uses mathematical modelling based on epidemiological data from four high-
101	burden settings (Côte d'Ivoire, Mozambique, Uganda, and Zimbabwe) to estimate the effect
102	on mortality of alternative programmatic cotrimoxazole strategies.
103	• The model incorporates the HIV status of the infant, perinatal and postnatal transmission
104	rates, testing rates, and mortality benefits from trial evidence for cotrimoxazole and
105	antiretroviral therapy (ART) across six different programmatic strategies: maintaining current
106	recommendations; reducing the duration of cotrimoxazole provision to three, six, nine or
107	twelve months; or starting cotrimoxazole only once a child tests positive for HIV.
108	We demonstrate that changing the current strategy is predicted to increase mortality in all
109	four settings, with the greatest increase in mortality in countries with the highest vertical
110	transmission rates.
111	Increased predicted mortality persisted in sensitivity analyses considering conservative
112	model estimates, although cotrimoxazole had fewer predicted benefits when vertical

	transmission rates were lowered, testing coverage improved or uptake of cotrimoxazole was
	reduced.
What [	Do These Findings Mean?
•	Changing the current strategy of cotrimoxazole provision for all children born to mothers
	with HIV is estimated to increase mortality in these four high-burden settings to varying
	degrees as countries continue to scale up Prevention of Mother to Child Transmission of HIV
	(PMTCT) and EID coverage.
•	Cotrimoxazole continues to provide important protection to children who acquire HIV and
	are missed by gaps in the test-to-treatment cascade, but does not replace the importance of
	timely testing and treatment.
•	Our study is limited by lack of cost-effectiveness analysis, lack of data on cotrimoxazole
	uptake, and limited antimicrobial resistance surveillance data in sub-Saharan Africa.
•	Policymakers need to weigh the risks and benefits of cotrimoxazole prophylaxis through any
	change to current recommendations, noting that these differ across settings: where lower
	vertical transmission rates and improved testing and treatment uptake occurs, the estimated
	mortality benefits of cotrimoxazole are attenuated.
	What I

## 130 Introduction

131

132 Vertical transmission of HIV occurs during pregnancy, labour, delivery, and breastfeeding. Despite 133 substantial reductions in vertical transmission globally due to increased uptake of antiretroviral 134 therapy (ART) among pregnant and breastfeeding women, transmission rates remain at 9% for 135 Eastern and Southern Africa and 21% for Western and Central Africa [1]. Poor uptake of prevention 136 of mother-to-child transmission (PMTCT) interventions arises due to late antenatal booking, low 137 rates of HIV testing and ART initiation, and disengagement with services during pregnancy or 138 breastfeeding [2]. Infants acquiring HIV have rapid disease progression, with over 50% mortality by 139 two years of age without infant ART [3]. Given ongoing high transmission rates, limited PMTCT 140 uptake, and rapid progression in undiagnosed children, programmatic strategies are needed to 141 reduce morbidity and mortality among children born to mothers with HIV, until elimination of 142 vertical transmission is achieved.

143 Cotrimoxazole is an inexpensive, well-tolerated, broad-spectrum antibiotic, which is recommended in World Health Organization (WHO) guidelines for all infants born to mothers with HIV from age 4-6 144 weeks until the end of HIV-exposure – typically defined as the end of breastfeeding, 18 months of 145 146 age, or conclusive determination of being HIV-free [4,5]. There is strong evidence of mortality benefit 147 from receiving cotrimoxazole among children with HIV. The CHAP trial demostrated a 43% reduction 148 in mortality in ART-naïve children, and the ARROW trial showed that benefits of cotrimoxazole 149 persist despite immune reconstitution on long-term ART [6,7]. Conversely, there is no evidence of mortality benefit from cotrimoxazole among children who are HIV-exposed but uninfected (HEU) [8, 150 151 9]. Furthermore, there are concerns about antibiotic resistance and microbiome dysbiosis with 152 cotrimoxazole use [10]. Given the distinct cotrimoxazole strategy required in each group, there is a 153 critical need to identify and distinguish children with HIV from children who are HEU across different 154 periods of transmission.

155 HIV testing for children has improved substantially over the past two decades. However, only 62% of 156 infants globally currently receive the recommended virological test within two months of birth [1]. 157 Overall, 40% of children with HIV therefore remain undiagnosed [11]. Even where infants are tested, 158 challenges remain across the testing-to-treatment cascade. These include lengthy turnaround times 159 for results, lack of integration with child health services, loss to follow-up, and delayed ART initiation 160 [12,13]. Vertical transmission through prolonged breastfeeding now accounts for over half of 161 transmissions in some settings, and necessitates longitudinal testing [2]. WHO guidelines encourage 162 testing of HIV-exposed children at nine months of age and after complete cessation of breastfeeding 163 [4].

164 A recent systematic review highlighted the lack of mortality benefit from cotrimoxazole for children 165 who are HEU [14]. However, in settings with insufficient PMTCT and inadequate early infant 166 diagnosis (EID) programmes, there is a substantial population of undiagnosed infants with HIV, who 167 may benefit from cotrimoxazole prophylaxis to reduce mortality. In other settings, where PMTCT uptake and EID coverage are high, and the majority of infants are HEU, the risk-benefit balance of 168 169 cotrimoxazole may differ. Therefore, given these competing concerns, the optimal duration of 170 cotrimoxazole prophylaxis needs to be determined. Here, we model the mortality impact of 171 alternative cotrimoxazole strategies in four high-burden settings.

- 172
- 173 Methods

174

175 Model Structure

176

177 We constructed a deterministic compartmental model with a decision tree to compare alternative 178 cotrimoxazole prophylaxis strategies for children who are HIV-exposed. The model aimed to mimic 179 epidemics in four high-burden countries: Zimbabwe (ZWE), Côte d'Ivoire (CIV), Mozambique (MOZ) 180 and Uganda (UGA). These countries represent differing sub-Saharan African contexts and have sufficient information to enable estimates for the model parameters. The model structure and all 181 182 estimates or assumptions applied are shown in Fig 1 and Supplementary Table S1. The study did not 183 have a prospective protocol. This study is reported as per the Transparent reporting of a 184 multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guideline (S1 Checklist).

185

186 The model estimates mortality from 6 weeks of age, when cotrimoxazole initiation is recommended, 187 to 24 months of age. Testing timepoints were assigned at 6 weeks (defined as EID), at 9 months and 188 at 18 months (defined as end of breastfeeding, EoB). At 6 weeks, infants are categorised according to 189 whether they have acquired perinatal HIV and whether they undergo early infant diagnosis. Children 190 who are HIV-free at 6 weeks may acquire HIV through breastfeeding and may or may not receive additional HIV testing at 9 months and end of breastfeeding. Cotrimoxazole was provided based on 191 192 programmatic strategy (Fig 1B). If the child was diagnosed with HIV, cotrimoxazole was started in 193 conjunction with ART. ART was initiated only after a positive HIV test and was not initiated after 194 negative or missed tests (i.e., for undiagnosed cases). Disease progression was incorporated through 195 survival probabilities for children with HIV and children who are HIV-exposed uninfected, extracted 196 from trial data and natural history studies [3,15]. Mortality occurs at each stage of the model, and 197 depends on current age, HIV status, ART use and cotrimoxazole use. We defined model parameters 198 for HIV transmission, coverage of EID and ART uptake using epidemiological data, as outlined below,

while the effects of cotrimoxazole and ART on mortality were derived from trials and meta-analyses(Supplementary Table 1) [2,3,15-18].

201

202 Compartments were created to compare strategies of receiving cotrimoxazole: (1) from age 6 weeks 203 to end of breastfeeding (current WHO strategy; base case), (2) from 6 weeks to 12 months, (3) from 6 204 weeks to 9 months, (4) from 6 weeks to 6 months, (5) from 6 weeks to 3 months, and (6) only once a 205 positive HIV test result is confirmed. In all strategies, we assume that infants testing positive for HIV 206 will start cotrimoxazole.

207

The primary outcome of deaths among children who are HIV-exposed from age 6 weeks to 2 years is expressed as (1) percentage mortality, (2) risk ratio compared to the current strategy, (3) excess deaths per year relative to the current strategy, and (4) excess annual deaths per 100,000 compared to the current strategy. The number of infants who are HIV-exposed in each country was calculated based on the number of live births and proportion of mothers living with HIV [19].

213

214 Data Sources and Parameters

215

216 We included parameters to reflect child HIV status based on UNAIDS perinatal and postnatal 217 transmission rates. The probability of an HIV test yielding a positive result was based on age-specific 218 transmission rates, obtained from country-specific UNAIDS estimates from the most recent year with 219 available data for all countries, including six-week transmission rates (MOZ 6%, ZWE 5%, CIV 4%, and 220 UGA 3%) [2]. For postnatal transmission, we calculated the cumulative probability of acquiring HIV by 221 age 9 months (MOZ 3.4%, ZWE 1.7%, CIV 1.7%, UGA 1.3%), and by the end of breastfeeding (MOZ 222 4.1%, ZWE 2.0%, CIV 2.1%, UGA 1.6%), based on derived weekly transmission rates from country-223 specific final vertical transmission rates and breastfeeding duration, making the assumption that 224 postnatal transmission rates were consistent over time [16]. 225

EID rates at 6 weeks were derived from country-specific UNAIDS estimates (MOZ 82.9%, ZWE 75.9%,

227 UGA 66.2%, CIV 60.8%) [16]. Since data on subsequent testing are not available, we assumed that

228 80% of children undergoing EID would have a 9-month test, and 50% would have an EoB test, as

these children would likely be engaged in the test-to-treatment cascade. For children not undergoing

EID at 6 weeks, we assumed the probability of subsequent testing was much lower (10% for 9-month

- test, 30% for EoB), as these children were likely less engaged with services. We derived the
- 232 proportion of children starting ART after a positive HIV test result based on point-of-care and
- standard-of-care testing coverage and corresponding ART uptake from a recent meta-analysis [17].

234	
235	Scenarios
236	
237	To estimate mortality, we considered several scenarios: (1) children with HIV diagnosed by EID, (2)
238	children with HIV not yet diagnosed (due to missed 6-week, 9-month and/or EoB tests) or with
239	postnatal acquisition after an earlier negative test, and (3) children who are HIV-exposed and
240	uninfected.
241	
242	In the first scenario, children with known positive HIV status after EID started cotrimoxazole, and
243	77% received ART based on a recent meta-analysis [17]. We applied a 43% mortality reduction
244	following cotrimoxazole initiation based on results of the CHAP trial [7], and a 76% mortality
245	reduction following ART initiation based on the CHER trial, to underlying mortality estimates [3,18].
246	
247	In the second scenario, children had undiagnosed HIV and did not therefore receive ART. We based
248	the survival probability on a pooled analysis of natural history studies conducted prior to the
249	availability of ART [3], and applied a 43% mortality reduction due to cotrimoxazole alone. With the
250	same rationale as in the first scenario, for 77% of children diagnosed with HIV (by 9 month or EoB
251	testing), we applied mortality reduction of 76% from ART and 43% from cotrimoxazole.
252	
253	In the third scenario, we derived mortality estimates for children who are HEU from an individual
254	pooled analysis [15], and applied no mortality reduction due to cotrimoxazole, based on trial data
255	[8,9].
256	
257	Sensitivity Analyses
258	
259	To explore uncertainties in the model assumptions, we conducted sensitivity analyses by adjusting
260	estimates of cotrimoxazole uptake, mortality reduction from cotrimoxazole, vertical transmission
261	rates (perinatal and postnatal), and EID testing rates. For cotrimoxazole, we considered the effect of
262	lower uptake (40%, 60% and 80% of HIV-exposed children starting cotrimoxazole at age 6 weeks)
263	compared to 100% uptake in the base model. For mortality effects of cotrimoxazole, we altered the
264	base case assumption of 43% mortality reduction, derived from the CHAP trial, which compared
265	cotrimoxazole and placebo among hospitalised children with HIV in Zambia. Since CHAP included
266	very few infants, meaning mortality reductions are uncertain in children <12 months old, we used
267	conservative estimates of 15%, 20%, 25%, 30%, 35%, 40% mortality reduction from cotrimoxazole to
268	test a range of assumptions. To consider future progress in the prevention of MTCT, we reduced

269 perinatal MTCT in 1% decrements to 0% and, separately, reduced postnatal MTCT rates in 0.5% 270 decrements to 0%. Finally, we increased EID coverage in 10% increments, from current country rates 271 up to 100%, to estimate the mortality benefits of cotrimoxazole with improved testing coverage over 272 time. In a final sensitivity analysis, we combined the variables above to create a conservative estimate of effects, assuming low levels of cotrimoxazole uptake (40%), low ascribed mortality 273 reduction from cotrimoxazole (15%), low perinatal (1%) and postnatal (1%) vertical transmission, and 274 275 optimal EID coverage (100%). 276 277 Data access and ethics 278 The model was constructed in Microsoft Excel, is freely available at https://osf.io/8kjgp/ and can be 279 280 adapted for other settings. No ethical approval was sought for this modelling study. 281 282 Results 283 284 Modelling the current WHO strategy, predicted mortality was 5.58% for Zimbabwe, 5.59% for Côte d'Ivoire, 5.78% for Mozambique and 5.39% for Uganda. Limiting cotrimoxazole exposure from 6 285 286 weeks to 3 months of age, resulted in higher predicted mortality in each setting compared to the 287 current strategy: Zimbabwe (increase in predicted mortality from 5.58% to 5.83%, risk ratio (RR) 1.04, 288 predicted excess mortality rate 246 deaths per 100 000 infants HIV-exposed, or 334 excess annual deaths), Côte d'Ivoire (from 5.59% to 5.90%, RR 1.05, 304 deaths per 100 000, 118 excess deaths), 289 290 Mozambique (from 5.78% to 6.11%, RR 1.06, 328 deaths per 100 000, 928 excess deaths), and 291 Uganda (from 5.39% to 5.60%, RR 1.04, 209 deaths per 100 000, 466 excess deaths); Table 1 and Fig 2. Similar effects were observed for six-, nine- and twelve-month strategies: in each case, predicted 292 293 infant mortality increased compared to the current policy, with the number of excess deaths lower 294 with longer durations of cotrimoxazole prophylaxis (Table 1, Fig 2). 295 296 A programmatic strategy of no routine prophylaxis, and instead initiating cotrimoxazole only once 297 HIV is diagnosed, led to the greatest increase in predicted mortality across settings: Zimbabwe 298 (increase in predicted mortality from 5.58% to 5.84%, RR 1.05, predicted excess mortality rate 260

deaths per 100 000 infants HIV-exposed, 352 excess annual deaths), Côte d'Ivoire (from 5.59% to

300 5.91%, RR 1.06, 322 deaths per 100 000, or 125 excess deaths), Mozambique (from 5.78% to 6.12%,

301 RR 1.06, 339 deaths per 100 000, or 961 excess deaths), and Uganda (from 5.39% to 5.61%, RR 1.04,

302 221 deaths per 100 000, 491 excess deaths); Table 1.

## 304 Sensitivity Analyses

305

306 Sensitivity analyses for Mozambique are shown in Fig 3. Reducing cotrimoxazole uptake to 40%, 307 predicted excess mortality was lower overall, but the fewest predicted deaths still occurred under 308 the current strategy of universal cotrimoxazole provision. Lowering the efficacy of cotrimoxazole in 309 5% intervals, to as little as 15% predicted mortality reduction (compared to 43% in the CHAP trial), 310 the current strategy continued to have the lowest number of predicted deaths. When EID coverage 311 was increased to 100%, the current strategy still had the lowest predicted mortality, compared to 312 alternative approaches of shorter durations of cotrimoxazole, although predicted excess mortality 313 reduced overall. To explore the effect of reaching and exceeding MTCT elimination targets, we 314 reduced rates for both perinatal and postnatal vertical transmission to zero. Finally, a combined 315 conservative estimate of low cotrimoxazole coverage (40%) and efficacy (15%), low vertical transmission (2%) and high EID (100%), designed to model a plausible future scenario in each 316 317 country, showed the current strategy still led to fewer predicted deaths, though effects were 318 attenuated. 319 320 Predicted mortality effects remained consistent across countries in all our sensitivity analyses.

321 Mozambique has the highest vertical transmission rate of the four countries (13.5%), and high EID 322 coverage (82.9%). If uptake was as low as 40% in Mozambique, starting cotrimoxazole only after a 323 positive HIV test is estimated to result in 369 excess annual deaths compared to the current strategy 324 (Fig 3). Figures for sensitivity analysis in Cote d'Ivoire (Fig S3.4), Zimbabwe (Fig S3.2), and Uganda (Fig 325 S3.7) are available in the Supplement. Uganda has the lowest vertical transmission rate (5.9%) and 326 EID coverage of 66.2%. Further reducing perinatal and postnatal MTCT without changing EID is 327 estimated to result in 311 and 251 excess annual deaths, respectively, if a strategy of starting 328 cotrimoxazole only after a positive HIV test was deployed. Cote d'Ivoire has the lowest EID coverage 329 of the four countries (60.8%) and vertical transmission of 7.8%. In the most optimistic consideration, 330 if EID coverage was increased to 100%, 3-month provision of cotrimoxazole is predicted to result in 331 51 excess annual deaths, in part due to continued vertical transmission through breastfeeding. In 332 Zimbabwe, where the vertical transmission rate (8.7%) is similar to the regional estimate for Eastern and Southern Africa, a conservative ascribed mortality reduction to cotrimoxazole of 15% would still 333 334 result in 352 excess annual deaths when cotrimoxazole is only started after a positive HIV test result. 335

336 Discussion

338 Our study suggests that changing the current cotrimoxazole policy for children born to mothers with 339 HIV is predicted to result in more deaths across the four modelled high-burden settings representing 340 different epidemic contexts. The highest increase in mortality is predicted to occur with no routine 341 cotrimoxazole provision (ranging from predicted excess mortality rate of 221 per 100 000 for Uganda 342 to 339 per 100 000 for Mozambique). These predicted effects persisted, but were attenuated, when 343 modelling lower cotrimoxazole uptake, smaller mortality benefits from prophylaxis, higher EID 344 coverage, and lower perinatal and postnatal vertical transmission. These effects are driven entirely 345 by the benefits of cotrimoxazole for infants who acquire HIV. Even as the epidemic context matures 346 and most infants now remain HIV-free, many countries still have slow progress towards elimination 347 targets. This study demonstrates the important 'safety net' that cotrimoxazole may provide for 348 children who are missed by the test-to-treat cascade in these settings.

349

350 Recent studies have questioned the ongoing value of cotrimoxazole in settings where most children 351 born to women with HIV now remain HIV-free [8-10]. Our study shows that across these four 352 modelled settings, predicted mortality would increase by limiting provision of cotrimoxazole. When 353 comparing modelled strategies, the highest predicted mortality occurred under an alternative 354 strategy of providing no universal prophylaxis, and instead starting cotrimoxazole only after a 355 positive infant HIV test result. This is driven by high predicted mortality among infants with HIV who 356 are not picked up by testing, and therefore not started on ART or cotrimoxazole [6,7]. Predicted 357 mortality increased to different degrees when cotrimoxazole was given universally but for a shorter 358 duration than currently. This is due to inadequate EID coverage, vertical transmission through 359 breastfeeding after an initial negative test, and shortening cotrimoxazole duration during a period 360 when disease progression among children with HIV remains rapid [3]. While the benefits of retaining 361 the current strategy persisted even with suboptimal cotrimoxazole coverage, reflecting the reality in 362 many settings, there were fewer benefits with low coverage, emphasising the continued effort needed to retain infants in care [20]. When comparing countries, Mozambique had the highest 363 364 predicted excess mortality and greatest number of excess annual deaths under alternative 365 cotrimoxazole strategies. This likely reflects high perinatal and postnatal transmission in 366 Mozambique compared to the other modelled countries. Conversely, Uganda has the lowest MTCT 367 rates, having made significant progress towards the elimination of paediatric HIV, and lowest 368 predicted increase in mortality with alternative cotrimoxazole strategies. Mozambique has the 369 highest EID testing rate but also had the greatest estimated increase in predicted mortality in our 370 models [16]. Taken together, this suggests that while increased testing coverage is advantageous, continued focus should be placed on interventions to reduce vertical transmission. Where vertical 371 372 transmission does occur, timely testing and initiation of antiretroviral treatment remains a

373 cornerstone of care. Countries with ongoing high rates of transmission would be most affected by374 any change in cotrimoxazole strategy.

375

There are several strengths and limitations to the analysis. Our model was developed with up-to-376 377 date, publicly available epidemiological estimates. These were supplemented by data extracted from the highest available levels of evidence. The model incorporates multiple aspects of transmission, 378 379 testing and treatment uptake and mortality, and has been developed in an accessible format which 380 can be adapted to other settings. Assumptions in the model were interrogated in sensitivity analyses. Although our effects of cotrimoxazole were derived from the CHAP trial – which enrolled children 381 382 after infancy in the pre-ART era – fewer predicted deaths occurred under the current strategy even 383 when the estimated mortality reduction from cotrimoxazole was as low as 15%. There are limited 384 randomised controlled trial data for cotrimoxazole among breastfed infants with HIV, but it is 385 unlikely that mortality benefits are substantially lower than in the original CHAP trial, given the more 386 rapid disease progression at this age, lack of prognostic markers, and higher risk of Pneumocystis 387 jirovecii pneumonia. Our sensitivity analysis shows that, even if this assumption is untrue and the 388 benefits are much lower, the current policy leads to fewer predicted deaths than a revised policy of 389 shorter (or no) prophylaxis. There are also limitations to this analysis. There are several parameters 390 for which data were not available (e.g., the probability of having a 9-month test if early infant 391 diagnosis has been missed). We assumed equal uptake of cotrimoxazole regardless of final child HIV 392 status, but it is likely that children most likely to acquire HIV are the least engaged in care and are 393 therefore less likely to receive cotrimoxazole. Countries achieving 95-95-95 testing and treatment 394 targets and Path to Elimination of MTCT goals were not modelled and may no longer require routine 395 cotrimoxazole given that few infants acquire HIV and those who do are most likely to be missed by 396 testing [21].

397

398 We only modelled mortality increases following reductions in cotrimoxazole provision, given the 399 known benefits of cotrimoxazole for children with HIV; however, our goal was to quantify the 400 magnitude of mortality increase for each strategy across epidemic contexts to provide policymakers 401 with population estimates when considering guideline revisions. We recognise, however, that our 402 model did not incorporate the potential risks of cotrimoxazole, such as antimicrobial resistance, as 403 mortality effects are difficult to quantify given limited quality data from sub-Saharan Africa [22]. 404 There is evidence that cotrimoxazole use in infants who are HEU leads to antimicrobial resistance, 405 including one small study showing cross-class resistance to amoxicillin, but no evidence of major 406 microbiome dysbiosis from available data [23]. Although there are estimates of deaths attributable 407 to resistance for specific antibiotics in several global regions [24], it is difficult to model what

408 proportion of these deaths would be averted in each of our scenarios, particularly as it remains 409 unclear whether cotrimoxazole resistance is reversible to a clinically relevant level with decline in use 410 [25]. Estimates of pathogen-specific deaths attributable to AMR from cotrimoxazole in sub-Saharan 411 Africa in the post-neonatal period range from 0.0 (0.0-0.1) per 100 000 for Proteus spp. to 15.07 (2.3-412 31.8) per 100 000 for Streptococcus pneumoniae, but even collectively these estimates are much 413 lower than the excess deaths modelled in our programmatic scenarios from restricted cotrimoxazole 414 use. Responsive country-level surveillance is required to evaluate local resistance data in the context 415 of evolving HIV epidemics. Lastly, this study did not consider the economic implications of the 416 proposed strategies. Future research should investigate the potential cost savings and the financial 417 impacts of implementing each strategy on national budgets [26].

418

419 Countries need to continue to strengthen the test-to-treat cascade, to ensure timely testing and ART 420 initiation, in order to reduce morbidity and mortality among infants who are HIV-exposed. However, 421 our models show that cotrimoxazole still remains an important part of the package of care. Decisions 422 around appropriate provision of cotrimoxazole to infants who are HIV-exposed require a pragmatic, 423 public health approach with difficult decisions that weigh risks and benefits that differ across 424 settings. Results from this model may be considered as part of the breadth of evidence which help 425 inform policymaker decisions. Though there has been progress in prevention of paediatric HIV, the 426 'last mile' to elimination is particularly challenging. Furthermore, in many high-burden settings, 427 testing coverage is not universal, making it difficult to reliably distinguish infants who are HIV-428 infected or HEU. Individualised algorithms dependent on testing contingencies may be unrealistic 429 given resource and service limitations at most low-level health facilities. The current programmatic 430 cotrimoxazole strategy provides important benefits for the small number of high-risk infants who still 431 acquire HIV through vertical transmission and are missed due to gaps in the test-to-treat cascade. As 432 demonstrated in the sensitivity analysis for each strategy, lower vertical transmission rates and 433 improved testing and treatment uptake attenuate the predicted increase in mortality. This 434 demonstrates the importance of considering how vertical transmission should inform cotrimoxazole 435 policy: in the context of high ongoing transmission, the current universal cotrimoxazole prophylaxis 436 approach is predicted to lead to substantially fewer deaths than alternative strategies, while settings 437 with low transmission rates may derive less benefit from universal cotrimoxazole prophylaxis. 438 Therefore, hybrid cotrimoxazole policies may be a consideration noting we did not model countries 439 achieving HIV elimination targets or with strong test-to-treat cascades. Further research is required 440 to better understand cotrimoxazole coverage for children who are HIV-exposed; to determine the 441 proportion who are subsequently found to be living with HIV; to better understand community 442 values and preferences; and to identify barriers to engagement with the test-to-treat cascade.

Finally, cost-effectiveness analysis informed by national programme cost data is required to better
understand the most optimal health investment and cost per death averted and economic impact of
each strategy.

In conclusion, despite impressive progress in prevention of vertical HIV transmission, elimination is not yet in sight in most high-burden settings. Priorities include maintaining optimal care and ART for mothers; providing postnatal HIV prophylaxis for infants; and ensuring timely testing and linkage to care. However, cotrimoxazole continues to provide a vital safety net for infants who acquire HIV but are not tested or started on ART. Our data suggest that changing the current strategy of universal cotrimoxazole provision for all infants who are HIV-exposed would increase predicted mortality to varying degrees across the four modelled countries, depending on vertical transmission rates and test-to-treatment cascade coverage. Policymakers need to balance the possible negative effects of cotrimoxazole with potential excess deaths resulting from changes in programmatic use depending on their specific context. Acknowledgements This work was originally presented at the International Workshop on HIV Pediatrics 2021. 

medRxiv preprint doi: https://doi.org/10.1101/2023.12.19.23300271; this version posted December 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 470 References

471 1. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2022. Geneva: UNAIDS, 2022. 472 2. Joint United Nations Programme on HIV/AIDS. Start Free, Stay Free, AIDS Free Final report on 473 2020 targets. 2021.

474 Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of 3. 475 infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 476 2004;364(9441):1236-43. doi: 10.1016/S0140-6736(04)17140-7. PubMed PMID: 15464184.

477 4. World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of 478 co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: 479 recommendations for a public health approach: December 2014 supplement to the 2013

480 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 481 World Health Organization; 2014.

482 5. Church JA, Fitzgerald F, Walker AS, Gibb DM, Prendergast AJ. The expanding role of co-483 trimoxazole in developing countries. Lancet Infect Dis. 2015;15(3):327-39. Epub 20150121. doi: 484 10.1016/S1473-3099(14)71011-4. PubMed PMID: 25618179.

485 6. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo 486 K, et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J 487 Med. 2014;370(1):41-53. doi: 10.1056/NEJMoa1214901. PubMed PMID: 24382064; PubMed Central 488 PMCID: PMCPMC4264559.

489 7. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as 490 prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind 491 randomised placebo-controlled trial. Lancet. 2004;364(9448):1865-71. doi: 10.1016/S0140-492 6736(04)17442-4. PubMed PMID: 15555666.

493 Daniels B, Coutsoudis A, Moodley-Govender E, Mulol H, Spooner E, Kiepiela P, et al. Effect of 8. 494 co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in 495 South Africa: a randomised controlled, non-inferiority trial. Lancet Glob Health. 2019;7(12):e1717-496 e27. doi: 10.1016/S2214-109X(19)30422-X. PubMed PMID: 31708152.

497 9. Lockman S, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S, et al. Effect of co-trimoxazole 498 on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, 499 randomised, placebo-controlled trial. Lancet Glob Health. 2017;5(5):e491-e500. doi: 10.1016/S2214-500 109X(17)30143-2. PubMed PMID: 28395844; PubMed Central PMCID: PMCPMC5502726.

501 Daniels B, Kuhn L, Spooner E, Mulol H, Goga A, Feucht U, et al. Cotrimoxazole guidelines for 10. 502 infants who are HIV-exposed but uninfected: a call for a public health and ethics approach to the 503 evidence. Lancet Glob Health. 2022;10(8):e1198-e203.

Teasdale CA, Zimba R, Abrams EJ, Sachathep K, Ndagije F, Nuwagaba-Biribonwoha H, et al. 504 11. 505 Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, 506 Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the 507 cross-sectional Population-based HIV Impact Assessment surveys. Lancet HIV. 2022;9(2):e91-e101. 508 doi: 10.1016/S2352-3018(21)00291-5. PubMed PMID: 35120641.

509 12. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-510 1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more 511 cost-effective interventions. BMC Med. 2011;9:59. Epub 20110520. doi: 10.1186/1741-7015-9-59. 512 PubMed PMID: 21599888; PubMed Central PMCID: PMCPMC3129310.

513 Chatterjee A, Tripathi S, Gass R, Hamunime N, Panha S, Kiyaga C, et al. Implementing services 13. 514 for Early Infant Diagnosis (EID) of HIV: a comparative descriptive analysis of national programs in four 515 countries. BMC Public Health. 2011;11:553. Epub 20110713. doi: 10.1186/1471-2458-11-553. 516 PubMed PMID: 21749730; PubMed Central PMCID: PMCPMC3161890.

517 Wedderburn CJ, Evans C, Slogrove AL, Rehman AM, Gibb DM, Prendergast AJ, et al. Co-14.

518 trimoxazole prophylaxis for children who are HIV-exposed and uninfected: a systematic review. J Int

519 AIDS Soc. 2023;26(6):e26079. doi: 10.1002/jia2.26079. PubMed PMID: 37292018; PubMed Central

520 PMCID: PMCPMC10251133.

perpetuity. It is made available under a CC-BY 4.0 International license .

521 15. Arikawa S, Rollins N, Jourdain G, Humphrey J, Kourtis AP, Hoffman I, et al. Contribution of Maternal Antiretroviral Therapy and Breastfeeding to 24-Month Survival in Human 522 523 Immunodeficiency Virus-Exposed Uninfected Children: An Individual Pooled Analysis of African and 524 Asian Studies. Clin Infect Dis. 2018;66(11):1668-77. doi: 10.1093/cid/cix1102. PubMed PMID: 29272387; PubMed Central PMCID: PMCPMC5961296. 525 526 Joint United Nations Programme on HIV/AIDS. UNAIDS data 2021. Geneva: UNAIDS, 2021. 16. 527 Luo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical effect of point-of-care HIV diagnosis in 17. 528 infants: a systematic review and meta-analysis. Lancet. 2022;400(10356):887-95. doi: 529 10.1016/S0140-6736(22)01492-1. PubMed PMID: 36116479. 530 Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral 18. 531 therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233-44. doi: 532 10.1056/NEJMoa0800971. PubMed PMID: 19020325; PubMed Central PMCID: PMCPMC2950021. 533 World Bank. World development indicators 2022. https://data.worldbank.org/: The World 19. 534 Bank; 2022. Accessed 2022 Dec 2. 535 20. Mofenson LM, Cohn J, Sacks E. Challenges in the early infant HIV diagnosis and treatment 536 cascade. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2020;84:S1-S4. 537 21. Frescura L, Godfrey-Faussett P, Feizzadeh AA, El-Sadr W, Syarif O, Ghys PD, et al. Achieving 538 the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One. 2022;17(8):e0272405. Epub 539 20220804. doi: 10.1371/journal.pone.0272405. PubMed PMID: 35925943; PubMed Central PMCID: 540 PMCPMC9352102. 541 22. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, Gonzalez IJ, et al. 542 Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616. Epub 543 20170911. doi: 10.1186/s12879-017-2713-1. PubMed PMID: 28893183; PubMed Central PMCID: 544 PMCPMC5594539. 545 Powis KM, Souda S, Lockman S, Ajibola G, Bennett K, Leidner J, et al. Cotrimoxazole 23. 546 prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants 547 in a randomized controlled trial, Botswana. J Int AIDS Soc. 2017;20(3). doi: 10.1002/jia2.25021. 548 PubMed PMID: 29119726; PubMed Central PMCID: PMCPMC5810322. 549 24. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55. Epub 20220119. doi: 10.1016/S0140-550 551 6736(21)02724-0. PubMed PMID: 35065702; PubMed Central PMCID: PMCPMC8841637. 552 25. Pouwels KB, Batra R, Patel A, Edgeworth JD, Robotham JV, Smieszek T. Will co-trimoxazole 553 resistance rates ever go down? Resistance rates remain high despite decades of reduced co-554 trimoxazole consumption. J Glob Antimicrob Resist. 2017;11:71-4. Epub 20170731. doi:

555 10.1016/j.jgar.2017.07.013. PubMed PMID: 28774863.

556 26. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, et al. The cost-effectiveness of 557 cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008;22(6):749-57. doi:

558 10.1097/QAD.0b013e3282f43519. PubMed PMID: 18356605.

## 560 Tables and Figures

561

## 562 Table 1 Comparison of predicted mortality, between ages 6 weeks to 2 years, with different

563 programmatic cotrimoxazole strategies for children born to mothers with HIV. For the current WHO 564 strategy (base case) of providing cotrimoxazole (CTX) to all HIV-exposed children, mortality rate is 565 expressed in percent (%). Alternative strategies explored were (1) initiating cotrimoxazole at 6 weeks 566 and stopping at 12 months, (2) initiating cotrimoxazole at 6 weeks and stopping at 9 months, (3) 567 initiating cotrimoxazole at 6 weeks and stopping at 6 months, (4) initiating cotrimoxazole at 6 weeks 568 and stopping at 3 months, and (5) initiating cotrimoxazole prophylaxis only once a positive HIV test 569 result is confirmed. Mortality for alternative strategies are reported in comparison to the base case 570 (current strategy): risk ratio, excess mortality rate per 100 000 HIV-exposed infants, and excess

- 571 annual deaths. CTX = cotrimoxazole.
- 572 573

## 574 Scenarios considered were (1) children with HIV (diagnosed), (2) children with HIV (undiagnosed), or 575 (3) HEU. Superscripts denote applied mortality estimates: (a) age-specific baseline mortality 576 estimates for infants with HIV and no ART, based on Newell et al. [3]. (b) age-specific baseline

Fig 1 Schematic illustration of model structure (scenarios and strategies). Panel A (Scenarios):

577 mortality estimates for HIV-exposed uninfected infants based on Arikawa et al. [15], (c) 77% uptake

578 of ART following positive HIV test based on Luo et al. [17], (d) 76% mortality reduction from ART 579 based on CHER [18], (e) 43% mortality reduction from CTX in a child with HIV based on CHAP [7], (f)

580 0% mortality reduction from CTX in an HIV-exposed uninfected child based on Botswana and South

581 Africa trials [8, 9]. **Panel B (Strategies)**: Illustration of considered programmatic strategies. Pink 582 represents period of programmatic CTX provision. Blue represents period of risk of HIV transmission

583 due to breastfeeding (18 months). Strategies illustrated are (1) current WHO strategy (2) initiating

584 CTX at 6 weeks and stopping at 12 months, (3) initiating CTX at 6 weeks and stopping at 9 months, (4)

initiating CTX at 6 weeks and stopping at 6 months, (5) initiating CTX at 6 weeks and stopping at 3
months, and (6) initiating CTX prophylaxis only once a positive HIV test result is confirmed and the
child is started on ART. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis
at 6 weeks, 9mo = 9-month HIV test, EoB = end of breastfeeding.

589

590 Fig 2 Excess deaths per year by country under alternative cotrimoxazole strategies. Columns

591 represent additional deaths from each alternate strategy in comparison to the current WHO

592 programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 months, 9m =

- 593 9 months, 6m = 6 months, 3m = 3 months.
- 594

medRxiv preprint doi: https://doi.org/10.1101/2023.12.19.23300271; this version posted December 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

595 Fig 3 Sensitivity Analysis (Mozambique) – Conservative Scenarios. Sensitivity analysis exploring the 596 effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the 597 current WHO strategy for Mozambique: (1) Cotrimoxazole uptake at 40% rather than 100% assumed 598 in the base model, (2) Mortality reduction from cotrimoxazole while on antiretroviral therapy 599 decreased from 43% to 15% (3) Mortality reduction from cotrimoxazole while not on antiretroviral 600 therapy decreased from 43% to 15% (4) EID coverage increased to 100% rather than 82.9% EID 601 coverage for Mozambigue, (5) Perinatal MTCT reduced from to 6% to 1%, (6) Postnatal MTCT 602 decreased from 7.5% to 6.5%. (7) Conservative estimate concurrently combining sensitivity scenarios 603 1-6. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis at 6 weeks, MTCT 604 = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 605 606 Supplement Table S1: Model assumptions and data sources. CTX = cotrimoxazole, ART = 607 antiretroviral therapy, EID = early infant diagnosis at 6 weeks, ZIM = Zimbabwe, CIV = Cote d'Ivoire, 608 MOZ = Mozambique, UGA = Uganda. \*The authorship brings multidisciplinary expertise in paediatric 609 HIV (AJP, CE, DMG, CW, MP), epidemiology (MS, DMG), clinical trials (DMG, AJP, MP, MS) and policy 610 (SM, MP). 611 612 Fig S2.1 Predicted mortality percentage per year by country under alternative cotrimoxazole 613 strategies. Columns represent additional deaths from each alternate strategy in comparison to the 614 current WHO programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 615 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 616 617 Fig S2.2 Predicted excess mortality rate (per 100 000) per year by country under alternative 618 cotrimoxazole strategies. Columns represent additional deaths from each alternate strategy in 619 comparison to the current WHO programmatic strategy of providing cotrimoxazole to all HIV-620 exposed infants. 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months. 621 622 Fig S2.3 Predicted risk ratio per year by country under alternative cotrimoxazole strategies. 623 Columns represent additional deaths from each alternate strategy in comparison to the current WHO 624 programmatic strategy of providing cotrimoxazole to all HIV-exposed infants. 12m = 12 months, 9m = 625 9 months, 6m = 6 months, 3m = 3 months. 626 627 Fig S3.1 Sensitivity Analysis for Zimbabwe (Risk Ratios). Sensitivity analysis, for Zimbabwe, exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the 628 current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis 629

630 at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 631 3m = 3 months. 632 633 Fig S3.2 Sensitivity Analysis for Zimbabwe (Excess Deaths). Sensitivity analysis, for Zimbabwe, 634 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 635 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 636 637 months, 6m = 6 months, 3m = 3 months. 638 639 Fig S3.3 Sensitivity Analysis for Cote d'Ivoire (Risk Ratios). Sensitivity analysis, for Cote d'Ivoire, 640 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 641 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 642 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 643 months, 6m = 6 months, 3m = 3 months. 644 645 Fig S3.4 Sensitivity Analysis for Cote d'Ivoire (Excess Deaths). Sensitivity analysis, for Cote d'Ivoire, 646 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 647 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 648 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 649 months, 6m = 6 months, 3m = 3 months. 650 651 Fig S3.5 Sensitivity Analysis for Mozambique (Risk Ratios). Sensitivity analysis, for Mozambique, 652 exploring the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) 653 compared to the current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = 654 early infant diagnosis at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 655 months, 6m = 6 months, 3m = 3 months. 656 657 Fig S3.6 Sensitivity Analysis for Uganda (Risk Ratios). Sensitivity analysis, for Uganda, exploring the 658 effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the 659 current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis 660 at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 661 3m = 3 months. 662 Fig S3.7 Sensitivity Analysis for Uganda (Excess Deaths). Sensitivity analysis, for Uganda, exploring 663

the effect of varying assumptions on the Risk Ratio for deaths (6 weeks to 2 years) compared to the

current WHO strategy. CTX = cotrimoxazole, ART = antiretroviral therapy, EID = early infant diagnosis
at 6 weeks, MTCT = mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months,
3m = 3 months.

668

- Fig S4.1 Sensitivity Variable Cotrimoxazole Uptake, Zimbabwe. Risk ratio of mortality for varying
  risk reduction from cotrimoxazole uptake for Zimbabwe, (Risk Ratio). CTX = cotrimoxazole, 12m = 12
  months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
- 672

Fig S4.2 Sensitivity Variable – Risk Reduction from CTX, Zimbabwe. Risk ratio of mortality for varying
risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Zimbabwe,
(Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m =

676 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

677

Fig S4.3 Sensitivity Variable – Risk Reduction from CTX, Zimbabwe. Risk ratio of mortality for varying
risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Zimbabwe,
(Risk Ratio). Risk Reduction from 25%-60%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m =
12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

682

Fig S4.4 Sensitivity Variable – EID Testing, Zimbabwe. Risk ratio of mortality for varying probability
of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Zimbabwe, (Risk Ratio). EID = early
infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

686

Fig S4.5 Sensitivity Variable – Perinatal MTCT, Zimbabwe. Risk ratio of mortality for varying
probability of perinatal mother-to-child transmission (MTCT) for Zimbabwe, (Risk Ratio). MTCT =
mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

Fig S4.6 Sensitivity Variable – Postnatal MTCT, Zimbabwe. Risk ratio of mortality for varying
probability of post-natal mother-to-child transmission (MTCT) for Zimbabwe, (Risk Ratio). MTCT =
mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

Fig S4.7 Sensitivity Variable - Cotrimoxazole Uptake, Cote d'Ivoire. Risk ratio of mortality for varying
 risk reduction from cotrimoxazole uptake for Cote d'Ivoire, (Risk Ratio). CTX = cotrimoxazole, 12m =

697 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

699	Fig S4.8 Sensitivity Variable – Risk Reduction from CTX, Cote d'Ivoire. Risk ratio of mortality for
700	varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for
701	Cote d'Ivoire, (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral
702	therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
703	
704	Fig S4.9 Sensitivity Variable – Risk Reduction from CTX, Cote d'Ivoire. Risk ratio of mortality for
705	varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for
706	Cote d'Ivoire, (Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral
707	therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
708	
709	Fig S4.10 Sensitivity Variable – EID Testing, Cote d'Ivoire. Risk ratio of mortality for varying
710	probability of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Cote d'Ivoire, (Risk
711	Ratio). EID = early infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m
712	= 3 months.
713	
714	Fig S4.11 Sensitivity Variable – Perinatal MTCT, Cote d'Ivoire. Risk ratio of mortality for varying
715	probability of perinatal mother-to-child transmission (MTCT) for Cote d'Ivoire, (Risk Ratio). MTCT =
716	mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
717	
718	Fig S4.12 Sensitivity Variable – Postnatal MTCT, Cote d'Ivoire. Risk ratio of mortality for varying
719	probability of post-natal mother-to-child transmission (MTCT) for Cote d'Ivoire, (Risk Ratio). MTCT =
720	mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
721	
722	Fig S4.13 Sensitivity Variable - Cotrimoxazole Uptake, Mozambique. Risk ratio of mortality for
723	varying risk reduction from cotrimoxazole uptake for Mozambique, (Risk Ratio). CTX = cotrimoxazole,
724	12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
725	
726	Fig S4.14 Sensitivity Variable – Risk Reduction from CTX, Mozambique. Risk ratio of mortality for
727	varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for
728	Mozambique, (Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral
729	therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
730	
731	Fig S4.15 Sensitivity Variable – Risk Reduction from CTX, Mozambique. Risk ratio of mortality for
732	varying risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for

733	Mozambique, (Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral
734	therapy, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
735	
736	Fig S4.16 Sensitivity Variable – EID Testing, Mozambique. Risk ratio of mortality for varying
737	probability of HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Mozambique, (Risk
738	Ratio). EID = early infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m
739	= 3 months.
740	
741	Fig S4.17 Sensitivity Variable – Perinatal MTCT, Mozambique. Risk ratio of mortality for varying
742	probability of perinatal mother-to-child transmission (MTCT) for Mozambique, (Risk Ratio). MTCT =
743	mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
744	
745	Fig S4.18 Sensitivity Variable – Postnatal MTCT, Mozambique. Risk ratio of mortality for varying
746	probability of post-natal mother-to-child transmission (MTCT) for Mozambique, (Risk Ratio). MTCT =
747	mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
748	
749	Fig S4.19 Sensitivity Variable - Cotrimoxazole Uptake, Uganda. Risk ratio of mortality for varying risk
750	reduction from cotrimoxazole uptake for Uganda, (Risk Ratio). CTX = cotrimoxazole, 12m = 12
751	months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
752	
753	Fig S4.20 Sensitivity Variable – Risk Reduction from CTX, Uganda. Risk ratio of mortality for varying
754	risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Uganda,
755	(Risk Ratio). Risk reduction from 15%-43%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m =
756	12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
757	
758	Fig S4.21 Sensitivity Variable – Risk Reduction from CTX, Uganda. Risk ratio of mortality for varying
759	risk reduction from cotrimoxazole while infant with HIV is taking antiretroviral therapy for Uganda,
760	(Risk Ratio). Risk reduction from 15%-60%. CTX = cotrimoxazole, ART = antiretroviral therapy, 12m =
761	12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
762	
763	Fig S4.22 Sensitivity Variable – EID Testing, Uganda. Risk ratio of mortality for varying probability of
764	HIV-exposed infants undergoing Early Infant Diagnosis (EID) for Uganda, (Risk Ratio). EID = early
765	infant diagnosis at 6 weeks, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
766	

- 767 Fig S4.23 Sensitivity Variable Perinatal MTCT, Uganda. Risk ratio of mortality for varying
- 768 probability of perinatal mother-to-child transmission (MTCT) for Uganda, (Risk Ratio). MTCT =
- mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.
- 770
- 771 Fig S4.24 Sensitivity Variable Postnatal MTCT, Uganda. Risk ratio of mortality for varying
- probability of post-natal mother-to-child transmission (MTCT) for Uganda, (Risk Ratio). MTCT =
- mother-to-child transmission, 12m = 12 months, 9m = 9 months, 6m = 6 months, 3m = 3 months.

		Programmatic Strategy					
		Current	Alternative				
			CTX from 6 weeks to 12 months	CTX from 6 weeks to 9 months	CTX from 6 weeks to 6 months	CTX from 6 weeks to 3 months	Start CTX only after positive HIV test result
Mozambique	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.78 - -	5.91 1.02 131 371	5.95 1.03 174 492	6.07 1.05 295 835	6.11 1.06 328 928	6.12 1.06 339 961
Cote d'Ivoire	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.59 - -	5.72 1.02 127 49	5.76 1.03 172 67	5.85 1.05 254 98	5.90 1.06 304 118	5.91 1.06 322 125
Zimbabwe	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.58 - -	5.68 1.02 99 135	5.71 1.02 134 181	5.79 1.04 208 281	5.83 1.04 246 334	5.84 1.05 260 352
Uganda	Mortality (%) Risk Ratio Excess mortality rate (per 100000) Excess deaths per year	5.39 - -	5.48 1.02 87 193	5.51 1.02 117 261	5.57 1.03 177 394	5.60 1.04 209 466	5.61 1.04 221 491

Table 1



# Fig1A



Fig1B



Fig2



Fig3